In October 2025, we had 27 million won — roughly 19,000 dollars — and a decision to make.
We could use it to extend the runway of the consumer wellness brand we had been building for ten months. Or we could place it as a first inventory position in GLP-1 pharmaceutical wholesale.
The consumer brand had traction. It had 1.15 million views and $7,831 in first-month sales. It had a team that had built something from nothing in a category no Korean company had seriously tried to own globally. By any startup standard, it was progressing.
The GLP-1 opportunity had something different: it was a supply-demand mismatch in a market that was moving faster than the existing infrastructure could handle, and we happened to be in the right position to close the gap.
The asymmetric bet defined
I want to name the logic precisely because it is the logic I have used to make every significant business decision in my career, and because it is often confused with opportunism, which it is not.
An asymmetric bet has three characteristics. The downside is bounded and known — you can lose the investment, and you know exactly what that amount is. The upside is unbounded or at least dramatically larger than the downside. And you have an information or operational advantage that is not available to the average market participant.
The GLP-1 bet in October 2025 met all three criteria.
Downside: 27 million won. Known, bounded, survivable.
Upside: a position in what we believed would become the fastest-growing pharmaceutical category in Korea, at a moment when the supply chain was fragmented and the demand was accelerating.
Advantage: existing relationships in pharmaceutical distribution from our pharmacy operations, logistics capability, and a team that could move at a speed that legacy wholesale operators could not.
What happened next
Five months after placing that initial position, we had done 3.2 billion won in GLP-1 wholesale revenue.
In April 2026, we completed the acquisition of 도팜인, a pharmaceutical wholesale company. By June, the company that was losing money when we bought it was generating 6.7 billion won in monthly revenue and 1.2 billion won in monthly gross profit. We held six to eight percent of Korean tirzepatide distribution.
The 27 million won had, in seven months, become a business that generated more in a month than we had invested in total across all activities since founding 한아원 in November 2024.
What the bet was really about
I want to be honest about what made this work. It was not financial sophistication. We did not build a complex model or stress-test seventeen scenarios.
What we had was a clear read on a market signal — the GLP-1 supply chain was constrained and demand was real — and the operational capability to act on it faster than the incumbents.
That capability was built through months of work that looked, at the time, like ordinary operational infrastructure. The pharmacy relationships. The logistics systems. The regulatory knowledge. None of it was built for GLP-1 wholesale. All of it transferred.
This is the thing about asymmetric bets that most analysis misses: the bet is usually the small part. The advantage that makes the bet worth taking is built long before the opportunity appears.
The principle going forward
We are now applying the same logic to three new bets simultaneously: GLPH, a supplement line for GLP-1 users; Onyu, a supplement dispenser product for the North American market; and 한아원파트너스, a wellness influencer commerce platform.
Each of these bets has bounded downside. Each has upside that is dramatically larger. Each is supported by operational capability we have already built.
The 27 million won taught us something specific: that the size of the bet is not what matters. What matters is whether the three conditions are met.
When they are, you move.